piperaquine has been researched along with nevirapine in 2 studies
| Studies (piperaquine) | Trials (piperaquine) | Recent Studies (post-2010) (piperaquine) | Studies (nevirapine) | Trials (nevirapine) | Recent Studies (post-2010) (nevirapine) |
|---|---|---|---|---|---|
| 638 | 227 | 497 | 3,212 | 509 | 1,108 |
| Protein | Taxonomy | piperaquine (IC50) | nevirapine (IC50) |
|---|---|---|---|
| Chain B, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
| Chain A, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
| Chain A, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
| Chain A, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
| Chain B, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
| Chain A, Reverse transcriptase/ribonuclease H | Human immunodeficiency virus 1 | 1.165 | |
| Prothrombin | Bos taurus (cattle) | 1.15 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 BH10 | 1.4504 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 2 (ISOLATE ROD) | 2.05 | |
| Gag-Pol polyprotein | HIV-1 M:B_HXB2R | 1.4353 | |
| Imidazoleglycerol-phosphate dehydratase | Saccharomyces cerevisiae S288C | 1.7 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.181 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 0.181 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.69 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.7 | |
| Microsomal triglyceride transfer protein large subunit | Homo sapiens (human) | 5.75 | |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | 0.18 | |
| Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | 2.071 | |
| Protease | Human immunodeficiency virus 1 | 0.101 | |
| Reverse transcriptase | Human immunodeficiency virus 1 | 3.995 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Achan, J; Arinaitwe, E; Charlebois, E; Clark, TD; Dorsey, G; Havlir, D; Ikilezi, G; Kakuru, A; Kamya, MR; Muhindo, MK; Mwangwa, F; Rosenthal, PJ; Ruel, T; Tappero, JW | 1 |
| Banda, CG; Kalilani-Phiri, L; Khoo, SH; Lalloo, DG; Macuacua, S; Maculuve, S; Mallewa, J; Mukaka, M; Mwapasa, V; Piqueras, M; Sevene, E; Terlouw, DJ; Vala, A | 1 |
2 trial(s) available for piperaquine and nevirapine
| Article | Year |
|---|---|
Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children.
Topics: Antimalarials; Artemisinins; Child, Preschool; Cohort Studies; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lopinavir; Malaria; Male; Nevirapine; Parasitemia; Quinolines; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Uganda | 2014 |
Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium falciparum uncomplicated malaria in adult patients on antiretroviral therapy in Malawi and Mozambique: an open label non-randomized interventional trial.
Topics: Adolescent; Adult; Alkynes; Anti-Retroviral Agents; Antimalarials; Artemisinins; Benzoxazines; Cyclopropanes; Drug Combinations; Female; Humans; Malaria, Falciparum; Malawi; Male; Middle Aged; Mozambique; Nevirapine; Plasmodium falciparum; Quinolines; Young Adult | 2019 |